arrow
J

Jacques Bénichou

universite paris-saclay and universite rouen-normandie
H指数:69
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dual Antiplatelet Therapy beyond 1 Year after a Myocardial Infarction Compared with Low-Dose Aspirin Alone: A 3-Year Follow-Up Cohort Study Within the French SNDS Nationwide Claims Database

心肌梗死后超过1年的双重抗血小板治疗与单独使用低剂量阿司匹林的比较: 法国SNDS全国索赔数据库中的3年随访队列研究

2026-01-230
PRE
Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris

利妥昔单抗在落叶型天疱疮患者中的长期疗效与安全性,并与寻常型天疱疮进行比较

2025-04-010
PRE
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients

环磷酰胺与利妥昔单抗在获得性血友病A中根除抑制剂的比较: 108例患者的随机试验

2024-05-017
OAAI
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy Follow-Up of the Ritux 3 Trial
2024-03-017
PRE
Efficacy of Methotrexate Alone vs Methotrexate Plus Low-Dose Prednisone in Patients With Alopecia Areata Totalis or Universalis A 2-Step Double-Blind Randomized Clinical Trial
2023-04-016
OA
Anti-BP180 IgG antibody ELISA values correlate with adverse pregnancy outcomes in pemphigoid gestationis
2023-03-067
OAAI
The priming effect of repetitive transcranial magnetic stimulation on clinical response to electroconvulsive therapy in treatment-resistant depression: a randomized, double-blind, sham-controlled study
2021-09-2810
PRE
International multicentre observational study to assess the efficacy and safety of a 0.5 mg kg-1 per day starting dose of oral corticosteroids to treat bullous pemphigoid
2021-09-0212
OAAI
CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC)
2021-06-1016
OAAI
Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study
2021-05-010
PREAI
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy A Post Hoc Analysis of a Randomized Clinical Trial
2020-05-0143
OAAI